Arvind Gupta

Arvind Gupta is a prominent venture capitalist based in San Francisco, California, known for his significant contributions to the biotechnology sector. As a Partner at Mayfield Fund, he co-leads the Engineering Biology practice, focusing on investments in science-based companies with the potential to make a substantial impact on human and planetary health. His portfolio includes pioneering companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite, Catalog, and Memphis Meats. Prior to his role at Mayfield, Gupta founded IndieBio, the world's largest biotech accelerator, where he invested in over 136 companies within five years, redefining the pace and possibilities of early-stage biotech. Under his leadership, IndieBio expanded to New York and grew to a team of fifteen investment professionals. Gupta holds a B.S. in Genetic Engineering from the University of California, Santa Barbara, and has been honored with the F50 Global Award for Impact in HealthTech Innovation. He is also the author of 'Decoding the World: A Roadmap for the Questioner' and has been a guest lecturer at institutions such as UCSF, MIT, and Harvard. His work has been profiled in global media outlets including Bloomberg News, Forbes, and The Guardian UK. In addition to his professional achievements, Gupta is an accomplished athlete, having been a world champion in No Gi Brazilian Jiu-Jitsu in 2016, and has engaged in activities such as climbing El Capitan and big wave surfing. He is married with two daughters.

Innovative solutions addressing significant global challenges, Strong scientific and technical foundations, Scalable business models with potential for substantial impact, Commitment to sustainability and ethical practices